Although antihistamines help many people, chronic inducible urticaria remains difficult to manage for some patients. That’s why ongoing research is essential.

The EMBARQ ColdU and SD Study is investigating barzolvolimab, an injectable medication being evaluated in a Phase 3 trial. Researchers aim to learn whether this investigational therapy can reduce symptoms in adults whose hives persist despite current treatments.

Clinical trials are carefully regulated, and participants receive detailed information about procedures, visits, and potential risks before enrolling. Research today helps shape tomorrow’s treatment options.